RxDoctor Payments Data

Angus Wilfong

Neurology with Special Qualifications in Child Neurology · Phoenix, AZNPI 1629158977

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $280,321 of the $348,359 with a category attached, or 80.5%. Livanova USA, Inc. accounts for 83.8% of it on its own, with 12 other manufacturers making up the rest. Among neurology with special qualifications in child neurology clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$348,359in general payments, 2019–2025

Across 361 payments — averaging $964.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Livanova USA, Inc.$292K
  • Sunovion Pharmaceuticals Inc.$18K
  • Greenwich Biosciences, Inc.$17K
  • UCB, Inc.$8K
  • Neurelis, Inc.$6K
  • SK Life Science, Inc.$5K
  • plus $2K from 7 others
$361,977in research payments, 2019–2025

Across 123 payments — averaging $2942.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Takeda Pharmaceuticals U.S.A., Inc.$166K
  • SK Life Science, Inc.$145K
  • Immedica Pharma US, Inc.$43K
  • Medtronic$5K
  • Livanova USA, Inc.$2K

What the payments were for

  • Consulting fees$15,4214%
  • Speaking & faculty fees$280,32180%
  • Travel & lodging$42,60812%
  • Food & beverage$10,0083%
  • Education$10%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$348,359 in reported general payments places this provider in the 95th percentile of 49 neurology with special qualifications in child neurology providers in Arizona.

See all neurology with special qualifications in child neurology providers in Arizona

Most prescribed under Part D

DrugClaimsCost to plans & patients
XcopriCenobamate15$34,979
Lamictal OdtLamotrigine12$30,747

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SK Life Science, Inc.Xcopri$4,865$34,97915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 49 neurology with special qualifications in child neurology providers in Arizona.

Other neurology with special qualifications in child neurology in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →